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Screening and Assessment of
Cancer-Related Fatigue: An
Executive Summary and Road Map
for Clinical Implementation
Joy C. Cohn, PT1 ; Shana Harrington, PT, PhD2 ; Jeannette Q. Lee, PT, PhD3 ; Daniel Malone, PT, PhD4 ; Mary Insana Fisher, PT5
1

Good Shepherd Penn Partners, Philadelphia, PA; 2 Exercise Science Department, University of South Carolina, Columbia,
SC; 3 Department of Physical Therapy and Rehabilitation Science, University of California at San Francisco/San Francisco
State University, San Francisco, CA; 4 Physical Therapy Program, Department of Physical Medicine and Rehabilitation,
University of Colorado, Aurora, CO; and 5 Department of Physical Therapy, University of Dayton, Dayton, OH

Background: Cancer-related fatigue (CRF) prevalence is reported as high as 90%. Cancer-related fatigue is
multidimensional and associated with lower health-related quality of life. Effective screening and assessment
are dependent upon use of valid, reliable, and clinically feasible measures. This Executive Summary of the
Screening and Assessment of Cancer-related Fatigue Clinical Practice Guideline provides recommendations for
best measures to screen and assess for CRF based on the quality and level of evidence, psychometric strength
of the tools, and clinical utility. Methods: After a systematic review of the literature, studies evaluating CRF
measurement tools were assessed for quality; data extraction included psychometrics and clinical utility. Measurement tools were categorized as either screens or assessments. Results: Four screens are recommended:
European Organization of Research and Treatment of Cancer Quality of Life Questionnaire, the MD Anderson
Symptom Inventory, the Distress Thermometer, and the One-Item Fatigue Scale. Eight assessments are recommended: Functional Assessment of Chronic Illness Therapy—Fatigue, Piper Fatigue Scale—Revised, Brief
Fatigue Inventory, Cancer Fatigue Scale, Fatigue Symptom Inventory, Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form and CAT, and Multidimensional Fatigue Inventory-20.
Discussion: This Executive Summary is a synopsis of and road map for implementation of the Clinical Practice
Guideline for Screening and Assessment of CRF. Review of the full Clinical Practice Guideline is recommended
[10.1093/ptj/pzac120]. Additional research focused on responsiveness of instruments is needed in order to
consider them for use as outcome measures. Screening and assessing CRF will result in opportunities to improve the quality of life of individuals with cancer. (Rehab Oncol 2022;40:148–161) Key words: neoplasm,
psychometrics, tiredness
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One of the most common side effects of cancer treatment is cancer-related fatigue (CRF), which impacts nearly
all individuals with cancer at some point in the care continuum. The incidence of CRF ranges between 25% and
99% depending on the type, stage and treatment of the
cancer, and how the fatigue is diagnosed.1,2 The causes
of CRF are multifactorial, related to the cancer itself and
to treatments for cancer, are cumulative during treatment,
and may persist long after treatment has ended.3-5 The National Comprehensive Cancer Network (NCCN) defines
CRF as “a distressing, persistent, subjective sense of physical emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional
to recent activity and interferes with usual functioning.”6
Most researchers agree that for CRF to be diagnosed, the
fatigue must be present on a daily basis.7 Addressing CRF
is imperative because it can profoundly affect physical and
social functioning, treatment tolerance, and ability to work
during and after treatment.
The multidimensional nature of CRF often differentiates this fatigue from usual tiredness. Piper et al,8
in a 1998 publication on the Piper Fatigue Scale—
Revised, delineated several subjective domains in which
patients experience fatigue. These included the sensory
components of mental, physical, and emotional fatigue,
temporality (when fatigue occurs), intensity and severity
of fatigue and its impact on activities of daily living, and
an emotional component evaluating mood as it relates
to fatigue. In this publication, the authors revised an
original fatigue scale from those 5 to 4 subscales with 22
items after initial psychometric testing with validation
in the cancer population and called it the Piper Fatigue
Scale—Revised (PFS-R), which is a recommended scale of
this Clinical Practice Guideline (CPG). Other researchers
have subsequently defined the multidimensionality of
CRF as physical, emotional, and cognitive.9,10 Because
of the multidimensional nature of CRF, it is challenging
to diagnose. For more than 2 decades, the NCCN has
recommended regular screening for CRF.6 However, in
a stakeholder survey of patients with a cancer diagnosis
conducted as part of this clinical practice guideline work,
84% reported that CRF was an important issue, yet 77%
of these patients reported that they themselves brought
fatigue to the attention of their medical team.11 These
findings are corroborated in other studies.12,13
Oncology care providers must be able to properly
screen and/or assess CRF to provide effective intervention strategies throughout the cancer care continuum and
into survivorship. Accurate screening and/or assessment of
CRF is dependent upon measures that demonstrate strong
psychometric properties that are also efficient in clinical
administration.14 Ease of use, cost, and availability in multiple languages are important considerations for clinical
adoption. Currently, the identification of CRF is primarily by self-report questionnaires. These self-reports range
from simple screens that identify the presence of CRF to
more comprehensive assessments of the nature of CRF. After fatigue is identified, a comprehensive examination by a
Rehabilitation Oncology, Vol. 40, No. 4

medical doctor is warranted. This may include laboratory
work to identify possible medical causes of fatigue, such
as anemia, malnutrition, and pharmacological effects, or
psychological reasons such as depression is necessary.9,15
Once medical reasons for CRF are treated and/or ruled out,
referral to other providers to manage CRF is warranted.
Clinical practice guidelines offer the health care
provider guidance for clinical practice that encompasses
the whole of the evidence database. Clinical practice guidelines make recommendations based on the quantity and
quality of the evidence for practice and are underpinned
by a systematic review of the available evidence and an
assessment of the benefits and harms of alternative care
options. The intent is to reduce practice variation, move research into practice, and improve the overall quality of care
delivered.16 The Academy of Oncologic Physical Therapy,
with support from the American Physical Therapy Association, commissioned the development of a CPG identifying
the best screening and assessment tools for use in the management of CRF. The methodology related to the development of the CPG, the full list of recommendations with
associated details regarding the strength of recommendations, and psychometric data of screening and assessment
tools can be found in the full CPG.[10.1093/ptj/pzac120]
The purpose of this executive summary is to provide the
health care clinician with a road map for implementing the
recommendations of the CPG.
SCREENING VERSUS ASSESSMENT
Screening tools are generally unidimensional, easy to
administer and interpret, and are limited in scope, while assessment tools are multidimensional in scope, more complex, but provide much more information in evaluating
CRF.17 The value of a screen is that it can be quickly used
by disparate health care professionals to trigger a referral for more in-depth evaluation by the appropriate health
care professional. A thorough evaluation of CRF using assessment tools allows for a richer understanding of the
nature, source, and extent of the problem identified by a
screen. These findings can be used to drive treatment decisions. Because of the multidimensional information that
can be elicited by an assessment, the treatment plan can
then be more easily tailored to meet the patient’s specific
challenges. In addition, assessments, if psychometrically
tested and valid for this purpose, can be used to document
change with appropriate interventions during care. The
Figure provides a decision-making algorithm for screening and assessment of CRF in those with cancer.
Following best practices for CPG development, the
guideline development team made recommendations
incorporating benefits and harms, quality of the available
evidence, and psychometric strength of the included CRF
tools, while also considering clinical utility. Clinical utility
includes considerations such as time to complete, available languages, and cost to use. This executive summary
presents the findings for preferred clinical application
based on the Clinical Practice Guideline on Screening
Screening and Assessment of Cancer-Related Fatigue
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Fig. 1. Screening and assessment decision algorithm. EORTC indicates European Organization of Research and Treatment of Cancer;
MDASI, MD Anderson Symptom Inventory; VAS, Visual Analog Scale. This figure is available in color online (www.rehabonc.com).
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and Assessment of Cancer-related Fatigue published
in the Journal of Physical Therapy and Rehabilitation
(PTJ) [10.1093/ptj/pzac120]. Recommendation language
(should or may) guides the clinician to use a particular tool
but does not obligate its use. That is, highest rated tools
are denoted by should, and alternative tools are denoted
by may. The authors acknowledge that the greatest harm
is in not screening for and assessing CRF, which results in
missed treatment or patient education opportunities and
substandard clinical care of the individual with cancer.

good to excellent reliability and validity as well as comprehensive testing in the population of interest, while level
B is indicative of tools that have acceptable evidence with
good reliability and validity.
To determine which tool to use, consideration must be
given to the patient population, language, and point of care
along the survivorship continuum. See Tables 2 to 4 that
identify, by tool, the applicability across the care continuum (Table 2), types of cancer (Table 3), and translations
(Table 4). It must be pointed out that no screen or assessment has been psychometrically tested in all cancer types.

SCREENING AND ASSESSMENT MEASUREMENT
TOOL RECOMMENDATIONS

Screening Recommendations

A total of 25 (10 screening and 15 assessment) measures were included in the final CPG. The screening and
assessment tools with level A and level B recommendations have the highest quality and are recommended for
use (2 screening and 8 assessment); 2 additional Best
Practice-P tools for screening are also included on the basis of widespread clinical use. These recommended tools
are summarized in this executive summary (Table 1). To
be rated level A, a tool must demonstrate a preponderance
of high-quality studies and strong psychometrics such as

Following NCCN recommendations, screening for
CRF at every health care visit by any of the oncologic
team is appropriate and can be effective in noting a change
in status. This recommendation is especially useful during
active treatment and throughout the immediate posttreatment period, but once an individual transitions to longterm survivorship, screening less frequently but periodically remains important. Rehabilitation personnel might
note CRF symptoms warranting treatment if screening is
included in an evaluation of an unrelated musculoskeletal
impairment during survivorship. The active treatment

TABLE 1
CRF Tools—Final Recommendations
Tool Name

Grade

European Organization for Research and
Treatment of Cancer—Quality of Life
Questionnaire—Core 3019,20,24-28
MD Anderson Symptom Inventory29-33
Distress Thermometer & Associated Problem
List34
One-Item Fatigue Screen35

A

Functional Assessment of Chronic Illness
Therapy—Fatigue36-41

A

Piper Fatigue Scale—Revised8,42-48

A

Patient-Reported Outcomes Measurement
Information System—Short Form
Fatigue49-56
Brief Fatigue Inventory57-62

A

Cancer Fatigue Scale23,63-68

B

Fatigue Symptom Inventory23,68-72

B

Multidimensional Fatigue
Inventory-2022,73-78
Patient-Reported Outcomes Measurement
Information System—CAT Fatigue49-56

B

B
P
P

B

B

Notes on Recommendation
Screening Tools
Health care providers should use for screening cancer-related fatigue

May be used for screening cancer-related fatigue
Limited evidence (1 study); may be used for severe fatigue; should be followed
up with use of Associated Problem List if positive for DT ≥4.
Limited evidence (1 study); may be used for screening cancer-related fatigue
Assessment Tools
High level of evidence; good overall psychometrics; widely used with multiple
validated translations; missing useful elements such as responsiveness
measures
Should be used for initial assessment of cancer-related fatigue if at risk or referred
for cancer-related fatigue; strong psychometric data; some controversy on the
factor solution in different cultures
Short Form—Fatigue has significant evidence with strong psychometric support
for use as initial or ongoing assessment of CRF. The measure is easy to use and
translated into multiple languages.
Rehabilitation professionals may use to assess cancer-related fatigue when a
patient has a history of cancer
Instrument designed to assess 3 separate domains of fatigue; concerns with level
of evidence for psychometric properties; concerns about translation to other
languages or cultures that do not capture fatigue the same as English does.
Useful to assess fatigue but has a lower number of high-quality studies. Concerns
about translation to other languages or cultures that do not capture fatigue the
same as English does.
Acceptable quality (primarily level II studies) with good ease of use. Some
challenges with structural validity in languages other than English.
This computer-adapted testing form for fatigue is available for use on several
platforms; however, psychometrics are emerging and the cost associated with
use is high.

Abbreviations: A, strong obligation—should be used; B, moderate obligation—may be used; CAT, computer-adapted testing; CRF, cancer-related fatigue;
DT, Distress Thermometer; P, best practice—may be used.

Rehabilitation Oncology, Vol. 40, No. 4
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TABLE 2
Tool Applicability Across the Care Continuuma

Active
Treatment

Tool Name

Immediate
Posttreatment
Period

Screening Tools
Distress Thermometer & Associated Problem List34
European Organization for Research and Treatment of Cancer—Quality of
Life Questionnaire—Core 3019,20,24-28
MD Anderson Symptom Inventory29-33
One-Item Fatigue Screen35

√
√

√

√
√

√
√

Assessment Tools
Brief Fatigue Inventory57-62
Cancer Fatigue Scale23,63-68
Functional Assessment of Chronic Illness Therapy—Fatigue36-41
Fatigue Symptom Inventory23,68-72
Multidimensional Fatigue Inventory-2022,73-78
Piper Fatigue Scale—Revised8,42-48
Patient-Reported Outcomes Measurement Information System—Short
Form Fatigue49-56
Patient-Reported Outcomes Measurement Information System—Fatigue
CAT

√
√
√
√
√
√

√
√
√
√
√

Long-term
Survivorship

√
√

√
√

√

Abbreviation: CAT, computer-adapted testing.
a Active treatment: surgery, chemo, radiation; immediate posttreatment: completion of primary adjuvant treatment to the first year of recovery;18 and
long-term survivorship: 1 year and longer after diagnosis.

phase includes the surgical, chemotherapeutic, and radiation interventions, while immediate posttreatment is that
time from the completion of primary adjuvant treatment
through the first year of recovery; long-term survivorship
is 1 year after diagnosis and greater.18
Two tools for performing a screen are recommended
for use by health care professionals seeking to evaluate a
broad range of symptoms experienced by individuals diagnosed with cancer in order to efficiently capture the
challenges these individuals may be facing. These include
the European Organization of Research and Treatment of
Cancer Quality of Life Questionnaire and the MD Anderson Symptom Inventory. These screening tools provide the
health care provider with the ability to comprehensively
screen for multiple comorbidities that may require further
investigation, and by doing so in a single tool, are more
efficient than performing multiple separate screens.
European Organization of Research and Treatment
of Cancer—Quality of Life Questionnaire—30 Core
Questionnaire (EORTC-QLQ-C30)
Recommendation: Should be used to screen
Description: This is a 30-item quality-of-life questionnaire surveying multiple symptoms experienced
with cancer; 3 symptom items are specific to fatigue: (1) “Did you need to rest?”; (2) “Have
you felt weak?”; (3) “Were you tired?” Scoring
is not straightforward. Directions for calculating a
score are available in the scoring manual on their
Web site.
When to use: Active treatment.
Clinical utility: This measure takes less than 10
minutes to complete. Answering yes to any of
152
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the 3 fatigue questions indicates that fatigue is
present and further assessment is warranted. The
EORTC-QLQ-C30 is free to use with registration
as an academic user and can be found at: https:
//qol.eortc.org/questionnaire/eortc-qlq-c30/. Commercial users should contact EORTC through
this Web site for cost information. The minimal
detectable change for fatigue is reported as 11
points.19 The minimal clinically important difference for improving fatigue is 12 points and for
worsening fatigue is 9 points.20
MD Anderson Symptom Inventory (MDASI)
Recommendation: May be used to screen.
Description: A 13-item questionnaire designed to evaluate the severity and effect of symptoms related to
cancer and cancer treatment. Each question asks
the respondents to rate their response on a 0 to 10
scale in the past 24 hours. Three symptom items
relate to fatigue: (1) “Your fatigue (tiredness) at its
WORST”; (2) “Your disturbed sleep at its WORST;”
and (3) “Your feeling drowsy (sleepy) at its worst.”
The score is reported as the mean of the items
responded to as long as a majority (eg, 7 out of
13) have been answered. In comparison with other
symptoms assessed “Patients rated fatigue-related
symptoms as the most severe.”21
When to use: Across the care continuum.
Clinical utility: The validated cut points provide a description of the severity of the fatigue: 5 to 6 = moderate, and 7 and greater = severe fatigue. The measure can be completed in 2 to 5 minutes; however,
clinical utility is limited due a required licensing fee
Rehabilitation Oncology, Vol. 40, No. 4

Rehabilitation Oncology, Vol. 40, No. 4

Screening and Assessment of Cancer-Related Fatigue

153

√

√
√
√

√

√

√

√

√

√

√

√

√

√
√
√

√
√
√

√

√

√

√
√

√

√

Colorectal
√

Prostate

√

Breast

Abbreviation: CAT, computer-adapted testing.

Brief Fatigue Inventory57-62
Cancer Fatigue Scale23,63-68
Functional Assessment of
Chronic Illness
Therapy—Fatigue36-41
Fatigue Symptom
Inventory23,68-72
Multidimensional Fatigue
Inventory-2022,73-78
Piper Fatigue
Scale—Revised8,42-48
Patient-Reported Outcomes
Measurement Information
System—Short Form
Fatigue49-56
Patient-Reported Outcomes
Measurement Information
System—CAT Fatigue49-56

Distress Thermometer &
Associated Problem List34
European Organization for
Research and Treatment of
Cancer—Quality of Life
Questionnaire—Core
3019,20,24-28
MD Anderson Symptom
Inventory29-33
One Item Fatigue Screen35

Tool Name

√

√

√

√

√

√

√

√

√

√

√
√
√

√

√
√
√
√

√

√

Head
and
Neck

√

√

Lung

TABLE 3

Brain

√

√

√

√

√

√
√

Assessment Tools

√

√

Screening Tools

Urogenital

√

√

Myeloma

CRF Measurements—Validation in Cancer Types

√

√

√
√
√

√

√

Blood

√

√

√

√

√
√
√

√

√

Lymphoma

√

√
√

√

Bone

√

√

√

√

√
√

√

√

Gyneco-logic

√

√
√

Skin

√

√

√

Liver

√

√

√

√

Stomach
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Distress
Thermometer &
Associated
Problem List34
European
Organization for
Research and
Treatment of
Cancer – Quality
of Life
Questionnaire—
Core
3028,31-35,37
MD Anderson
Symptom
Inventory29-33
One-Item Fatigue
Screen35

Tool Name

√

Spanish

√

French

Chinese

√

TABLE 4

√

Korean

√

Arabic

√

Russian
Greek

√

√

Screening Tools

Japanese

√

Filipino

√

Taiwanese

Swedish
Italian

Foreign Language Translations of Recommended Screening and Assessment Tools for CRF
Portuguese

Ethiopian

Indonesian

Polish

German

Rehabilitation Oncology, Vol. 40, No. 4
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√

√

√

Spanish

√

√

French

Abbreviation: CAT, computer-adapted testing.

Brief Fatigue
Inventory57-62
Cancer Fatigue
Scale23,63-68
Functional
Assessment of
Chronic Illness
Therapy—
Fatigue36-41
Fatigue Symptom
Inventory23,68-72
General Fatigue
Scale82
Multidimensional
Fatigue Inventory2022,73-78
Piper Fatigue
Scale—
Revised8,42-48
Patient-Reported
Outcomes
Measurement
Information
System—Short
Form Fatigue49-56
Patient-Reported
Outcomes
Measurement
Information
System—CAT
Fatigue49-56

Tool Name

TABLE 4

√

√

√

√

√

√

Korean

Chinese

Arabic

Russian
Greek

√

√

Assessment Tools
√
√

Japanese
√

Filipino

√

√

Taiwanese

√

Swedish

√

√

Italian

Foreign Language Translations of Recommended Screening and Assessment Tools for CRF (Continued)

√

√

√

√

Portuguese
√

Ethiopian
√

Indonesian

√

Polish

√

German

of a minimum of $100, which can vary by clinic size
and number of users. The MDASI cannot be used or
reproduced without permission. It can be accessed
at: https://www.mdanderson.org/patients-family/
search-results.html?q=MDASI userguide.pdf#

for primary medical evaluation; a score 7/10 and
greater can indicate a marked decrease in physical
functioning.6 There is no cost for use.
Assessment Recommendations

For a quick screen, 2 “Best Practice” (Recommendation Strength P) tools are recommended by the CPG: The
Distress Thermometer and the One-Item Fatigue Scale. Although both of these tools have insufficient psychometric analysis to support a strong recommendation from the
guideline development group, both are extensively used
clinically and, since they are easy to implement, make a
good choice for quick screens.

Positive screens for CRF should be followed by referral to appropriate health care providers for assessment. For
rehabilitation providers evaluating individuals with CRF, 3
tools received the highest recommendation, A, and should
be used in practice, while 5 tools received a B recommendation, and may be used in practice.

The Distress Thermometer and Associated Problem
List (DT)

Recommendation: Should be used to assess.
Description: The FACIT-F is a 41-item questionnaire
covering multiple domains of health-related quality
of life with a 13-item fatigue specific domain subscale. All items are scored on a 0 to 5 Likert scale
and separate scores can be calculated for each domain subscale (including fatigue) or summed for a
total score with a higher score representing better
functioning or less fatigue.
When to use: Active treatment.
Clinical utility: The measure takes 15 minutes to complete and is free for both clinical and research use.
It can be completed verbally or in writing. When
based on a global perception of fatigue improvement, a change of 10 points in the FACIT-F score
had a sensitivity (73%) and specificity (78%), which
predicted a clinically important improvement. A
cutoff score of 34 with a range of 0 to 52 on the
fatigue domain subscale indicates CRF.

Recommendation: May be used to screen.
Description: The Distress Thermometer is an 11-point
Likert scale presented as a thermometer with 0 =
No distress and 10 = Severe distress, denoting overall distress experienced during cancer care. The
score is the number chosen. A cut point of 4 and
greater triggers the completion of the associated
Problem List, which is a 40-item multidimensional
list to identify the specific cause or causes of the
reported distress; fatigue is one of the items on the
problem list.
When to use: Active treatment and the immediate posttreatment period.
Clinical utility: If fatigue is checked on the associated
Problem List, this functions to alert the health care
provider that fatigue is a significant complaint. A
full assessment of fatigue or referral to an appropriate health care provider to complete assessment
is warranted. Determining the appropriate health
care provider can be made on the basis of other
symptoms checked on the Problem List. For example, if fatigue and another symptom in physical
concerns are checked, it is appropriate to refer to
physical therapy for further assessment; if fatigue
and another symptom among emotional concerns
are checked, a referral to social work may be warranted. It is free and readily available for use.
One-Item Fatigue Scale
Recommendation: May be used to screen.
Description: The One-Item Fatigue Scale is a numeric
or verbal rating scale in which the individual answers the question “Since your last visit, how would
you rate your worst fatigue on a scale of 0 to 10 with
0 = no fatigue and 10 = worst fatigue.” The score
is the number chosen.
When to use: Across the care continuum.
Clinical utility: Scoring: 0 = No fatigue, 1 to 3 = mild
fatigue, 4 to 6 = moderate fatigue, and 7 to 10 =
severe fatigue. A score of 4 and greater is a cut point
indicative of fatigue sufficient to trigger a referral
156
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Functional Assessment of Chronic Illness
Treatment—Fatigue (FACIT-F)

Piper Fatigue Scale—Revised (PFS-R)
Recommendation: Should be used to assess.
Description: The PFS-R is a 22 item numerically scaled
self-report questionnaire for assessing the current
level of fatigue experienced by the respondent. It
measures 4 domains of fatigue with each item rated
on a 0 to 10 scale from “None” to “A Great Deal.”
The domains include Behavioral/Severity or effect
on activities of daily living, Affective or emotional
effects of fatigue, Sensory or physical symptoms
of fatigue, and Cognitive/Mood subscale measuring mental and mood status. There are 4 additional
questions to elicit qualitative information regarding the respondent’s experience of fatigue. Subscale
and total scores are calculated by sum divided by
number of items for a total score between 0 and 10
with higher scores indicative of greater fatigue.
When to use: Active treatment and immediate posttreatment period.
Clinical utility: The written version takes 10 minutes
to complete and is available for free for both clinical
and research use: https://geriatrictoolkit.missouri.
edu/fatigue/PiperFatigueScale.pdf.
Rehabilitation Oncology, Vol. 40, No. 4

Patient-Reported Outcome Measurement
Information System (PROMIS) Fatigue—Short
Forms v1.0—Fatigue (4a, 6a, 7a, 7b, 8a, 13a)
Recommendation: Should be used to assess.
Description: There are 6 adult PROMIS Fatigue short
forms and the number (ie, 4a) designates how
many questions are in each form. The original adult
short form instrument was the 7a and measures
fatigue in the past 7 days as do forms 4a, 6a, and
8a.81 Short forms 7b and 13a are instruments that
measure daily fatigue.81 Items are scored on a
5-point Likert scale, with 1 = not at all, 5 = very
much, and summed, some items are reverse scored
such as item 7 in form 7a. Scoring is not straightforward. Refer for further information at: https://
www.assessmentcenter.net/ac_scoringservice or
https://www.healthmeasures.net/images/PROMIS/
manuals/PROMIS Fatigue Scoring Manual.pdf.
The PROMIS Fatigue-Short Forms are part of the
PROMIS system of self-report measures developed
by the National Institutes of Health (http://
www.healthmeasures.net/explore-measurementsystems/promis/intro-to-promis).
When to use: In the immediate posttreatment period.
Clinical utility: The PROMIS Fatigue-Short Form
instruments are short, easy to complete, and have
been translated into several languages. The instruments are available for free, though commercial
users must seek permission to use, reproduce, or
distribute the instrument. The PROMIS FatigueShort Form is part of the PROMIS system of
self-report measures and is available through a
number of different platforms38-40 (http://www.
healthmeasures.net/index.php?option=com_
content&view=category&layout=blog&id=71&
Itemid=817).

Cancer Fatigue Scale (CFS)
Recommendation: May be used to assess.
Description: This 15-item multidimensional scale
measures physical, affective, and cognitive fatigue.
Each question of the CFS is assessed on a 5-point
Likert scale where 1 = No and 5 = Very much;
Higher scores indicate greater fatigue. Scoring is
not straightforward. We suggest a review of the
published reference.49
Although no cut points are reported, some evidence
suggests that the CFS is responsive to change with
a minimally important difference ranging from 0.3
to 0.5.
When to use: During active treatment
Clinical utility: The CFS is estimated to take less than
2 minutes to complete and has been translated into
multiple languages. Cost information could not be
determined.
Multidimensional Fatigue Inventory 20 (MFI 20)
Recommendation: May be used to assess.
Description: The MFI 20 is a 20-item self-report tool
with multiple dimensions assessed including general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Each dimension has 4 questions with Likert scales for each
from 1 to 5, with a higher score indicating greater
fatigue.
When to use: Across the continuum.
Clinical utility: The written version takes about 5 to 10
minutes to complete. A free copy of the questionnaire was included in the original article published
by the developers and can also be obtained by contacting the developers.22 Direct correspondence to:
E.M.A. Smets Academic Medical Centre, University
of Amsterdam Department of Medical Psychology
Amsterdam, the Netherlands.

Brief Fatigue Inventory (BFI)
Recommendation: May be used to assess.
Description: The Brief Fatigue Inventory assesses fatigue in the previous 24 hours—both its severity
and its effect on daily functioning and social activities. It has 10 items that the respondent rates on a
scale from 0 to 10: 0 = “No Fatigue” to 10 = “As
bad as you can imagine.” A score is calculated from
the average of the item responses.
When to use: Active treatment and immediate posttreatment period.
Clinical utility: The BFI has published cutoff scores of
1 to 3 mild fatigue, 4 to 6 moderate fatigue, and 7 to
10 severe fatigue. The utility is limited because the
MD Anderson Web site states that there is a $100
licensing fee for its use in clinical settings. This
tool can be found at: https://www4.mdanderson.
org/symptomresearch/index.cfm?

Rehabilitation Oncology, Vol. 40, No. 4

Fatigue Symptom Inventory (FSI)
Recommendation: May be used to assess.
Description: The FSI is a 14-item questionnaire that
measures fatigue severity, frequency of fatigue, and
the perception of fatigue as interfering with an individual’s quality of life. The FSI also measures the
diurnal variation of fatigue, which is a unique feature of this tool. Fatigue severity is assessed using
4 items on a 0 to 10 scale (0 = “not at all fatigued;”
10 = “as fatigued as I could be”) within 4 areas:
most, least, average, and current fatigue. Frequency
is measured using 2 items: the number of days in
the past week (0-7) that a patient felt fatigued plus
the extent of each day on average he or she felt fatigued (0 = None of the day; 10 = The entire day).
Perceived interference is measured using 7 items
on a separate 0 to 10 scale (0 = No interference, 10
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= Extreme interference). The final item provides
qualitative information about potential daily diurnal patterns of fatigue. Each item on the FSI can
be scored individually, and the frequency and interference ratings can be summed to yield a total
subscale score.23
When to use: Across the care continuum.
Clinical utility: The FSI is free and takes about 5 minutes to complete.
Patient-Reported Outcomes Measurement
Information System Computerized Adaptive
Testing for Fatigue (PROMIS Fatigue CAT)
Recommendation: May be used to assess.
Description: This computer-adapted testing (CAT)
scale includes an item bank of 95 questions (a question plus respective response options); the respondent is first presented with an item of moderate
symptom severity and based on responses to previously administered items. The computer estimates
the domain score after each item, and when this
score reaches a predefined precision, the CAT stops.
Hence, patients need to answer only a small number of items (usually 5-7) per PROMIS item bank to
get an accurate and reliable T score.79 This allows
the system to identify the patient on the symptom
continuum within 4 to 12 items. The recall period
is over the past 7 days.
When to use: Immediate posttreatment period.
Clinical utility: Can be completed by the individual
without assistance but having a proxy complete
is acceptable. Limitations arise related to access
(requires access to the internet); despite efforts to
maximize efficiency of individual scales, clinically
useful combinations of PROMIS scales may take
too long (greater than 10 minutes) for older patients and patients with low technology literacy.
Despite rigorous effort to increase precision, patients with a lower literacy level may demonstrate
lower precision.80 Cost is an additional consideration, ranging from a few hundred to a few thousand
dollars per year depending on the institution.
CLINICAL IMPLEMENTATION
Cancer-related fatigue is the most commonly reported
side effect in the cancer population. Recognition that this
side effect can have significant effect on physical, cognitive,
and psychological function resulting in a decreased quality
of life during and beyond cancer treatment with obvious
societal implications is essential. Identification and quantification of CRF can be facilitated by the timely and judicious use of reliable and validated outcome measures to
screen and assess for its presence. These tools can then trigger referral for medical and effective rehabilitative strategies. Recommended screening tools provide opportunities
for the rapid determination of CRF by any health care
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provider, while the assessment tools describe the multidimensional nature of the experience of CRF and may allow for more goal-directed treatment planning. Clinicians
should practice caution in using these recommended tools
to measure outcomes as most do not have the necessary
psychometric testing related to sensitivity and specificity to
detect minimal clinically important differences. This Executive Summary provides the clinician with a road map for
implementation of these tools in their oncology practice.
Although we found a number of outcome measures,
which are valid and reliable for assessing CRF, the available
literature was too limited to allow us to generalize their use
across all cancer diagnoses or across the entire continuum
of cancer care. Few of these tools have been psychometrically tested in the survivorship phase of cancer care
where an increasing number of patients may experience
CRF years after their cancer treatment. Careful attention
to Tables 2 to 4 will guide the health care provider in
choosing the right tool.

CONCLUSION
This executive summary is intended to guide clinicians in selecting appropriate tools for use in the screening
and assessment of CRF. Too often, CRF is underdiagnosed
and underreported. Timely identification and evaluation of
CRF will greatly aid in its management, potentially reducing the survivor’s symptom burden and improving their
quality of life. Readers and clinicians are encouraged to
refer to the full CPG article for more detailed information
about each outcome measures merits, or lack thereof. It
is important to consider each patient’s clinical presentation, disease stage, and place in the cancer treatment and
survivorship spectrum when considering the appropriate
measure to use in CRF screening or assessment.
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